Pet Pharm Biotech Co., Ltd. (TPEX:7762)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
49.45
-5.35 (-9.76%)
At close: Mar 27, 2026
Market Cap2.53B -18.6%
Revenue (ttm)222.03M +69.9%
Net Income24.99M +72.3%
EPS0.46 +27.8%
Shares Out51.21M
PE Ratio107.50
Forward PEn/a
Dividend0.09 (0.18%)
Ex-Dividend DateAug 25, 2025
Volume286,076
Average Volume67,262
Open54.10
Previous Close54.80
Day's Range48.00 - 54.10
52-Week Range41.89 - 91.20
Betan/a
RSI11.58
Earnings DateApr 7, 2026

About Pet Pharm Biotech

Pet Pharm Biotech Co., Ltd. manufactures and sells pharmaceutical products. The company also engages in the research, development, and production of nuclear medicine drugs. Its products include FDG fluodeoxyglucose, naolixi, and sodium fluoride injections; and radioactive sodium iodide capsules. The company was founded in 2011 and is based in New Taipei City, Taiwan. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2011
Employees 45
Stock Exchange Taipei Exchange
Ticker Symbol 7762
Full Company Profile

Financial Performance

In 2025, Pet Pharm Biotech's revenue was 222.03 million, an increase of 69.88% compared to the previous year's 130.70 million. Earnings were 24.99 million, an increase of 72.25%.

Financial Statements